Transforming key account management in pharma: From engagement to value

There’s an uncomfortable truth at the heart of pharmaceutical commercial models: despite two decades of transformation, key account management (KAM) is still little more than a relabeled sales function for far too many organizations. 

Sometimes referred to as strategic customer group, customer-centric engagement, or an account-based commercial model, this approach typically assigns a few large accounts per account manager. But other than taking an account-based approach with specific sales targets, it isn’t that different from a traditional sales model. If brands want to leverage KAM and adapt it to the future of the industry, they’ll need to take a more value-based approach. 

KAM in name only 

Looking from the outside in, it would appear as though many pharma brands have successfully shifted from transactional sales to value-based engagement. Field forces have been reorganized. Titles have changed. Customer relationship management (CRM) systems have modernized and harmonized. But behind the curtain, commercial execution doesn’t necessarily look much different.  

While many organizations have rebranded traditional sales reps as account managers, few have fundamentally changed capabilities, incentives, or operating models. As a result, tactical interactions with customers are framed as “strategy,” and product conversations are masqueraded as partnerships. Partnerships and collaborations can’t be just about drug usage and formulary benefits. This excludes the context of the provider, ignores the real business challenges that providers are facing, and exacerbates trust issues with pharma’s true intent. This is compounded by the fact that brand leaders have continued to measure the efficacy of KAM roles on traditional metrics of field activity (e.g., calls per target, days in field) and overall sales growth.  

Internal confusion about what KAM is intended to achieve persists throughout many organizations, with unclear roles and fragmented ownership of customer relationships. Surprisingly, even in organizations with KAM roles, there’s rarely a single point of contact for key accounts, a single individual accountable for customer outcomes, or a clear operating model to solve customer challenges. As a result, KAM teams in many organizations are failing to show value—and executives are understandably questioning their purpose. 

Why KAM fails to address today’s access realities 

While pharma debates job descriptions, its customers have undergone a far more radical transformation. The typical pharma sales audience is no longer physicians in clinics visited by sales reps. Today, commercialization teams must consider the priorities of government, public, and private payer stakeholders; providers across various sites of care; intermediaries like pharmacy benefits managers and group purchasing organizations; and, of course, patients.  

Put simply: decision-making has shifted from individual prescribers to complex, multi-layered institutions with diverse—and often conflicting—economic, clinical, and operational priorities. 

Once passive recipients of care, patients are becoming active participants in their care journey. They demand convenience, transparency, and outcomes. They expect seamless experiences across the care journey and don’t hesitate to change their provider if their experience is suboptimal. Because providers are aware of this, they’ve started reorganizing their operations to focus on patient outcomes. Yet many pharma brands still organize around products. 

The core flaw: KAM as a “role” 

The central problem is conceptual. KAM in pharma is still treated as a role—a person responsible for managing a relationship. But today’s pharma stakeholders don’t need relationship managers. They need pharma executives to serve as: 

• System integrators: Connecting payers, providers, and other key parties in a fragmented healthcare delivery model 
• Value architects: Devising turnkey, end-to-end therapy solutions that provide real, timely value to patients and stakeholders 
• Outcome partners: Sharing risk and working together to drive positive outcomes, including reduced hospitalization, improved adherence, and lower cost of care 

No single individual, no matter how skilled, can achieve the above alone. It would require significant bandwidth and a multitude of skillsets needed to navigate payer economics, coordinate across care pathways, and align a variety of clinical, operational and financial stakeholders to get to the outcomes that matter.  

Yet pharma continues to pretend that a single individual deemed the “key account manager” can do exactly that. Unfortunately, it’s unrealistic and far-fetched from a structural, competency, and capabilities standpoint. 

Building a KAM ecosystem to deliver outcomes, not just products 

The future of KAM isn’t better people; it’s an ecosystem of people, processes, and systems. For years, pharma has focused on “customer experience” to make interactions smoother, more personalized, and tech-enabled. The missing link is that a great experience alone doesn’t translate into measurable value—great outcomes do.  

Health systems don’t need more pharma rep interactions or more tailored, personalized emails. They need support from pharma in addressing their critical needs: 

• Reduced hospitalizations  
• Improved adherence  
• Lower total cost of care  
• Better patient outcomes  

Pharma brands need to take a more holistic approach—going beyond selling therapies to supporting patient outcomes—and KAM must be the engine of that transition. Manufacturers will need to redefine compliance guardrails, reimagine internal ways of working to foster more collaboration across functions, and create joint KPIs with providers on outcomes that providers care about. 

From individual ownership to orchestrated engagement 

Today’s customer engagement is fragmented. Different teams across sales, medical, and market access approach the same account with different objectives, messages, and timelines. The result is confusion, duplication, and a deeply suboptimal customer experience. The future demands orchestration, coordination, and intentional engagement. 

Brands will need to invest in: 

• A unified account strategy  
• Shared objectives across functions
• Real-time data and insights 
• Clear governance of who engages when and why  

In this model, KAM isn’t the “owner” of the relationship. Instead, it coordinates across teams, building an overall strategy that incorporates every interaction into a coherent, value-driven narrative. 

From products to solutions  

Despite years of rhetoric, most companies still rely on the “clinical sell,” focusing on product features rather than customer needs. Many products fail to reach their potential because they lack a compelling value proposition. Few organizations are able to deliver advanced, customer-specific solutions because they lack clear data about what’s happening at the health system level and fail to work in partnership with providers to create custom solutions that fit their unique needs. When solutions are complicated by operational and legal complexity, providers are less likely to buy in.  

Brands should simplify their offerings and streamline the experience for providers and patients. They can start by focusing on these four broad categories: 

• Adherence programs tied to outcomes  
• Risk-sharing agreements with payers  
• Digital tools for patient monitoring  
• Care pathways redesigned in collaboration with health systems  

KAM must evolve from selling products to conceptualizing, designing, and delivering these solutions at scale—bringing providers to the table and rallying the internal teams and processes needed to bring these programs to market. 

The rise of the “account-first organization” 

What emerges from all of this is something radically different: the account-first organization. In this model, the account is the primary unit of strategy instead of the brand. Cross-functional teams are aligned to account objectives. Value propositions are co-created with customers. And success is measured in outcomes, not activity. 

As a structural redesign of the commercial model, this new approach demands new capabilities, incentives, and leadership mindsets. Most importantly, it requires letting go of a deeply ingrained belief that growth comes from selling more products and focusing instead on value.  

Most pharma companies have the resources, data, talent, and executive willingness to make this transition possible. But the intent now needs to translate into action. It’s far easier to rename roles, introduce new tools, and add dashboards than to commit to the much harder work of redesigning operating models, rewiring incentives, and challenging deeply held beliefs. Brands that successfully transform the KAM model will operate as partners in care delivery, drive measurable outcomes, and scale value creation.